{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010399","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.815849+00:00","generated_at":"2026-05-17T19:39:42.063989+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Scholar Rock Q2 loss $110M; apitegromab PDUFA Sept 22, 2025; positive EMBRAZE lean mass data","bullets":["FDA accepted apitegromab BLA under priority review; PDUFA target action date September 22, 2025.","Phase 2 EMBRAZE trial: apitegromab + tirzepatide preserved 54.9% more lean mass vs tirzepatide alone (p=0.001).","Q2 net loss $110M ($0.98/shr) vs $58.5M ($0.60/shr) in prior year; no revenue.","Cash $295M as of June 30, 2025; expected to fund operations into 2027.","Preparing for U.S. commercial launch upon potential approval; EMA MAA validated, EU launch anticipated 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010399","json":"https://secwatch.observer/filing/0001558370-25-010399.json","markdown":"https://secwatch.observer/filing/0001558370-25-010399.md","text":"https://secwatch.observer/filing/0001558370-25-010399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/0001558370-25-010399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:39:42.063989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}